Skip to content

Multifocal Lens Centration and Its Effect on Visual Performance in a Presbyopic Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02228109
Acronym
BUICK
Enrollment
35
Registered
2014-08-28
Start date
2014-12-31
Completion date
2015-04-30
Last updated
2015-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia

Brief summary

The purpose of this study is to use a corneal topographer, a device that is readily available in most optometric practices, in order to determine the position of the multifocal (MF) contact lens (CL) optics in relation to the optics of the eye. The specific purpose of this study is to evaluate if there is a relationship between the positioning of the optics of the study lenses and the objective and subjective visual performance as well as participant satisfaction. The MF CL lenses will be fitted to two groups of participants (previously unsuccessful vs. currently successful MF CL wearers). HYPOTHESES * The measurement of the power distribution acquired from the Medmont E300 corneal topographer is effective in determining MF CL lens centration and is a predictor of MF CL success. * There is a difference in MF CL centration, determined by corneal topography, between successful and unsuccessful MF CL wearers. * MF CL centration, determined by corneal topography, is correlated with visual performance, determined by ocular aberrometry, measures of visual acuity and subjective satisfaction.

Interventions

Acuvue Oasys for Presbyopia contact lenses worn

DEVICEPureVision2 for Presbyopia

PureVision2 for Presbyopia contact lenses worn

DEVICEBiofinity Multifocal

Biofinity Multifocal contact lenses worn

Sponsors

Johnson & Johnson Vision Care
CollaboratorUNKNOWN
University of Waterloo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
42 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

A person is eligible for inclusion in the study if he/she: 1. Is at least 42 years of age and has full legal capacity to volunteer; 2. Has read and signed an information consent letter; 3. Is willing and able to follow instructions and maintain the appointment schedule; 4. Has previous experience with wearing MF CLs; 5. Is able to be successfully fitted with all study lenses; 6. Has a vertex-corrected spherical distance prescription of +6.00 to 8.00D (inclusive) in both eyes; 7. Has a spectacle cylinder ≤0.75D in both eyes; 8. Requires a reading addition of ≥+1.00D;

Exclusion criteria

A person will be excluded from the study if he/she: 1. Is participating in any concurrent clinical or research study; 2. Has any known active\* ocular disease and/or infection; 3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study; 6. Is pregnant, lactating or planning a pregnancy at the time of enrolment; 7. Is aphakic; 8. Has undergone refractive error surgery; 9. Has monocular best-corrected VA of worse than 20/30 in each eye; 10. Has amblyopia or strabismus; 11. Has anisometropia \>2D between both eyes * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Design outcomes

Primary

MeasureTime frameDescription
DecentrationDay 1Decentration (in mm and axis of decentration) of the multifocal contact lens optical center relative to ocular reference points (e.g. the pupil center or the line of sight), determined using difference maps produced by the Medmont E300 corneal topographer.

Secondary

MeasureTime frameDescription
Visual Acuity (high contrast) at intermediate distanceDay 1Visual Acuity (high contrast) (logMAR) at intermediate distance 1m
Visual Acuity (high contrast) at nearDay 1Visual Acuity (high contrast) (logMAR) at near (0.4m)
Visual Acuity (low contrast) at distanceDay 1Visual Acuity (low contrast) at distance 6m
Visual Acuity (high contrast) at distanceDay 1Visual Acuity (high contrast) (logMAR) at distance 6m
Visual Acuity (low contrast) at nearDay 1Visual Acuity (low contrast) (logMAR) at near (0.4m)
Overall subjective rating of lens performance in real world tasksDay 1Participants rate overall satisfaction with vision with the contact lenses on a scale of 0-100, where 0=completely dissatisfied and 100=completely satisfied, after completing a series of real world tasks.
Ocular aberrometryDay 1Ocular aberrometry as measured by a LADARWave aberrometer
Visual Acuity (low contrast) at intermediate distanceDay 1Visual Acuity (low contrast) (logMAR) at intermediate distance 1m

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026